Luis Ruiz Guerrero

467 posts

Luis Ruiz Guerrero banner
Luis Ruiz Guerrero

Luis Ruiz Guerrero

@LRGuerr

Cardiologist. Inherited Cardiovascular Diseases. Cardiopatías y Aortopatías Familiares. @HUnivValdecilla H.U. Marqués de Valdecilla. Santander. 🇪🇸

Katılım Ocak 2020
110 Takip Edilen216 Takipçiler
Luis Ruiz Guerrero retweetledi
Ahmad Masri
Ahmad Masri@MasriAhmadMD·
ACACIA-HCM trial topline results - aficamten in nHCM. Incredibly proud and thankful to our patients and team for their commitment and hard work. This represents the first effective treatment for patients with nHCM. looking forward to seeing the full results. #CardioTwitter
Ahmad Masri tweet mediaAhmad Masri tweet media
English
4
30
75
4.9K
Luis Ruiz Guerrero retweetledi
JACC Journals
JACC Journals@JACCJournals·
Danicamtiv enhanced cardiac myosin function in vitro and was generally well tolerated in #DCM. Echo findings suggest improved contractility, with strongest responses in #MYH7 and TTN cohorts jacc.org/doi/10.1016/j.… #JACC #cvDCM
JACC Journals tweet media
English
1
10
40
5.1K
Luis Ruiz Guerrero retweetledi
American College of Cardiology
Limiting fluid intake may have no benefit for patients with #HeartFailure, according to findings from the FRESH-UP study presented during a Late-Breaking Clinical Trial session at #ACC25. Check out the key findings ➡️ bit.ly/3DYGHEl
American College of Cardiology tweet media
English
0
32
97
10.6K
Luis Ruiz Guerrero retweetledi
NEJM Evidence
NEJM Evidence@NEJMEvidence·
Cardiopulmonary exercise testing (CPET) has a unique role in the assessment of cardiopulmonary disease. @BrazileTiffany and colleagues review key CPET variables, protocols and clinical indications. eviden.cc/4aC6uOt
NEJM Evidence tweet media
English
1
109
287
45.7K
Luis Ruiz Guerrero retweetledi
NEJM
NEJM@NEJM·
Heart failure with preserved ejection fraction is noted for symptoms of heart failure, LVEF of at least 50%, and cardiac or structural abnormalities. Treatment includes diuretics and SGLT2 inhibitors. Learn more: nej.md/4h41K6k
NEJM tweet media
English
0
91
253
29.3K
Luis Ruiz Guerrero retweetledi
John Mandrola, MD
John Mandrola, MD@drjohnm·
This is nice work on an important question in EP. I have an idea about a subgroup. Mandrola theory of de novo AFlutter. If it occurs in pt w prior heart surgery, CTI likely enough. If no prior surgery, CTI + PVI better. #epeeps LOE 👆= opinion. #EPeeps
Rui Providência@rui_providencia

Should we isolate the pulmonary veins in all patients with atrial flutter? Does PVI replace the need for cavitricuspid isthmus isolation? Provocative findings in systematic led by Daniel Gomes. Great collaboration @SergeBoveda , @DhirajGuptaBHRS , et al. #Afib #atrialfibrillation

English
1
4
28
8.4K
Luis Ruiz Guerrero retweetledi
John Mandrola, MD
John Mandrola, MD@drjohnm·
As promised, here is a slew of content ...re the PLATO trial of ticagrelor vs clopidogrel in patients with ACS This all occurred in 2009, early in my critical appraisal learning. Revisiting PLATO controversy is super important--both clinically and epistemologically
English
2
11
64
13.6K
Luis Ruiz Guerrero retweetledi
American College of Cardiology
🗝️ Collecting a detailed family history and pertinent clinical data for patients with cardiomyopathies is needed to guide potential use of genetic testing. Read more key points on genetic testing for cardiomyopathies ➡️ bit.ly/4fho5vK #HeartFailure
English
1
6
16
2.9K
Luis Ruiz Guerrero retweetledi
JM Larrañaga
JM Larrañaga@xenux88·
2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee | Journal of the American College of Cardiology jacc.org/doi/10.1016/j.…
English
0
4
5
481